During the past decade, Montefiore Einstein Cancer Center conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 11 clinical trials were completed, i.e. on average, 84.6% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 7 clinical trials were completed. i.e. 233.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Montefiore Einstein Cancer Center" #1 sponsor was "Celgene" with 4 trials, followed by "Hoffmann-La Roche" with 2 trials sponsored, "Pfizer" with 2 trials sponsored, "AIDS Malignancy Consortium" with 1 trials sponsored and "Adlai Nortye Biopharma Co., Ltd." with 1 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Montefiore Einstein Cancer Center" #1 collaborator was "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "Center for International Blood and Marrow Transplant Research" with 1 trials as a collaborator, "National Cancer Institute (NCI)" with 1 trials as a collaborator, "Takeda Development Center Americas, Inc." with 1 trials as a collaborator and "The Emmes Company, LLC" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Montefiore Einstein Cancer Center" are "Myelodysplastic Syndromes" (3 trials), "Non-small Cell Lung Cancer" (2 trials), "Acute Myeloid Leukemia" (1 trials), "Acute-graft-versus-host Disease" (1 trials) and "Advanced Lymphoma" (1 trials). Many other conditions were trialed in "Montefiore Einstein Cancer Center" in a lesser frequency.

Most popular intervention types in "Montefiore Einstein Cancer Center" are "Drug" (18 trials), "Other" (4 trials), "Biological" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (2 trials), "Azacitidine" (2 trials), "Gemcitabine" (2 trials), "Pembrolizumab" (2 trials) and "Placebo" (2 trials). Other intervention names were less common.

The vast majority of trials in "Montefiore Einstein Cancer Center" are 17 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Montefiore Einstein Cancer Center". undefined are not yet recruiting, 3 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Montefiore Einstein Cancer Center, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Montefiore Einstein Cancer Center, 5 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".